Phthalic Acid

Phthalic Acid

SCHEMBL368309

C=CC(CC)C(=O)O.O=C(O)c1ccccc1C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
ALOX15 P16050 1/20 0.50
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
AKR1C3 P42330 2/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
RECQL P46063 1/20 0.41
MYC P01106 2/20 0.40
CYP2C19 P33261 1/20 0.40
NR4A1 P22736 1/20 0.40
HPGD P15428 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
HMGB1 P09429 1/20 0.39
CA4 P22748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL6055991 0.84 LMNA (0.41) ALDH1A1POLBKMT2AMEN1CYP2C19
Styrene SCHEMBL3758847 0.82 ALDH1A1 (0.50) ALDH1A1TDP1AKR1C3KMT2AMEN1
SCHEMBL14533808 0.80
SCHEMBL26620 0.80
Phthalic Acid SCHEMBL8517832 0.79 ALDH1A1 (0.47) ALDH1A1ALOX15POLBMAPTHDAC8
Phthalic Acid SCHEMBL27350994 0.79 ALDH1A1 (0.61) ALDH1A1ALOX15MAPTHDAC8TDP1
Ethylene SCHEMBL3936195 0.78 TSHR (0.36) ALDH1A1TDP1KMT2AMEN1CYP2C19
Phthalic Acid SCHEMBL10400552 0.77 ALDH1A1 (0.58) ALDH1A1ALOX15POLBMAPTHDAC8
Phthalic Acid SCHEMBL6065205 0.77 ALDH1A1 (0.64) ALDH1A1ALOX15POLBMAPTHDAC8
Phthalic Acid SCHEMBL9015687 0.76 ALDH1A1 (0.70) ALDH1A1ALOX15POLBMAPTHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542223-B1 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2015-09-23 EP claimed
US-20150086623-A1 CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION INCLUDING TAMSULOSIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND ORAL FORMULATION INCLUDING THE SAME SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) 2015-03-26 US claimed
US-20130052264-A1 CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION INCLUDING TAMSULOSIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND ORAL FORMULATION INCLUDING THE SAME SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) 2013-02-28 US claimed
EP-2542223-A2 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF Hanmi Science Co., Ltd. (KR) 2013-01-09 EP claimed
US-20120321709-A1 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2012-12-20 US claimed
US-20120015032-A1 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME HANALL PHARMACEUTICAL COMPANY, LTD. (KR) 2012-01-19 US claimed
WO-2011108826-A2 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI HOLDINGS CO., LTD. (KR) 2011-09-09 WO claimed
US-20110123612-A1 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER HANALL BIOPHARMA CO., LTD (KR) 2011-05-26 US claimed
US-20110117194-A1 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER HANALL BIOPHARMA CO., LTD. (KR) 2011-05-19 US claimed
US-20110111021-A1 PHARMACEUTICAL PREPARATION HANALL BIOPHARMA CO., LTD. (KR) 2011-05-12 US claimed
EP-2255797-A2 COMPOSITE PREPARATION HanAll Biopharma Co., Ltd. (KR) 2010-12-01 EP claimed
EP-2180891-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME Hanall Pharmaceutical Co., Ltd. (KR) 2010-05-05 EP claimed
US-20100047341-A1 COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY HANALL PHARMACEUTICAL CO., LTD. (KR) 2010-02-25 US claimed
EP-2079451-A1 COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY Hanall Pharmaceutical Co., Ltd. (KR) 2009-07-22 EP claimed
WO-2009022821-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME HANALL PHARMACEUTICAL COMPANY. LTD (KR) 2009-02-19 WO claimed
WO-2008044862-A1 COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY HANALL PHARMACEUTICAL CO., LTD. (KR) 2008-04-17 WO claimed
EP-0241178-B1 PHARMACEUTICAL COMPOSITION FOR TREATING PERIODONTAL DISEASES ROHTO PHARMACEUTICAL CO., LTD. (JP) 1992-01-08 EP claimed
EP-0241179-B1 PHARMACEUTICAL COMPOSITION FOR PERIODONTAL DISEASES ROHTO PHARMACEUTICAL CO., LTD. (JP) 1991-11-13 EP claimed
US-4981693-A Pharmaceutical composition for periodontal diseases ROHTO PHARMACEUTICAL CO., LTD. (JP) 1991-01-01 US claimed
US-4933182-A Pharmaceutical composition for treating periodontal ROHTO PHARMACEUTICAL CO. LTD. (JP) 1990-06-12 US claimed